Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Newly Diagnosed Multiple Myeloma (NDMM)”

47 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 47 results

Testing effectiveness (Phase 2)UnknownNCT04935580
What this trial is testing

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 20
Testing effectiveness (Phase 2)UnknownNCT00378755
What this trial is testing

Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM

Who this might be right for
Multiple Myeloma
Korean Multiple Myeloma Working Party 62
Early research (Phase 1)Not Yet RecruitingNCT07114432
What this trial is testing

RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma

Who this might be right for
Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCTNewly Diagnosed Multiple Myeloma (NDMM)
Tianjin Medical University Cancer Institute and Hospital 19
Not applicableLooking for participantsNCT06682156
What this trial is testing

Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients

Who this might be right for
Newly Diagnosed Multiple Myeloma
The First Affiliated Hospital of Soochow University 50
Early research (Phase 1)Study completedNCT03984097
What this trial is testing

Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Takeda 50
Testing effectiveness (Phase 2)Ended earlyNCT02720510
What this trial is testing

A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT04052880
What this trial is testing

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Who this might be right for
Newly Diagnosed Multiple Myeloma
Larysa Sanchez 17
Testing effectiveness (Phase 2)Study completedNCT02891811
What this trial is testing

Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

Who this might be right for
Multiple Myeloma
Arbeitsgemeinschaft medikamentoese Tumortherapie 124
Not applicableLooking for participantsNCT07296627
What this trial is testing

Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients

Who this might be right for
Newly Diagnosed Multiple Myeloma (NDMM)
Peking University People's Hospital 500
Testing effectiveness (Phase 2)Looking for participantsNCT06103838
What this trial is testing

18F-Fluciclovine PET/CT in Multiple Myeloma

Who this might be right for
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI) 60
Very early researchUnknownNCT05840107
What this trial is testing

Study of FasT CAR-T GC012F Injection NDMM Patients

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 18
Testing effectiveness (Phase 2)Looking for participantsNCT07107529
What this trial is testing

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Who this might be right for
Multiple Myeloma (MM)
European Myeloma Network B.V. 150
Large-scale testing (Phase 3)Looking for participantsNCT06679101
What this trial is testing

Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Who this might be right for
Multiple MyelomaNewly Diagnosed Multiple Myeloma
GlaxoSmithKline 520
Not applicableLooking for participantsNCT07087964
What this trial is testing

Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients

Who this might be right for
Newly Diagnosed Multiple Myeloma (NDMM)
Universiteit Antwerpen 120
Not applicableLooking for participantsNCT06099912
What this trial is testing

Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM

Who this might be right for
Multiple MyelomaFrailty
FengYan Jin 131
Testing effectiveness (Phase 2)Active Not RecruitingNCT05850286
What this trial is testing

VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 20
Large-scale testing (Phase 3)Looking for participantsNCT06879379
What this trial is testing

KPD Consolidation After ASCT in NDMM Patients

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Peking University People's Hospital 202
Testing effectiveness (Phase 2)WithdrawnNCT04258683
What this trial is testing

Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

Who this might be right for
Multiple Myeloma
Canadian Myeloma Research Group
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06963866
What this trial is testing

Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Xuzhou Medical University 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04891809
What this trial is testing

Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM

Who this might be right for
Newly Diagnosed Multiple Myeloma
Arbeitsgemeinschaft medikamentoese Tumortherapie 198
Next Page